Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size
| Autor: | Giulia Maresca, Giovanna Luciani, Nicola Panocchia, Maurizio Bossola, Enrico Distasio, Carlo Vulpio, Silvia Cacaci |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Paricalcitol
medicine.medical_specialty Kidney Calcitriol business.industry medicine.medical_treatment Urology Parathyroid hormone Hematology medicine.disease Endocrinology medicine.anatomical_structure Nephrology Internal medicine medicine Secondary hyperparathyroidism Parathyroid gland Hemodialysis business Kidney disease medicine.drug |
| Zdroj: | Hemodialysis International. 15:69-78 |
| ISSN: | 1492-7535 |
| DOI: | 10.1111/j.1542-4758.2010.00514.x |
| Popis: | Paricalcitol is more effective than calcitriol in hemodialysis patients (HD) with secondary hyperparathyroidism (SHPT), but it is not effective in some of them. We have investigated the relationship between paricalcitol responsiveness and parathyroid gland (PTG) size. Thirty HD with SHPT treated previously with calcitriol for at least 6 months were switched to paricalcitol (1:4 conversion ratio). Parathyroid gland number and size (maximum longitudinal diameter [MLD] of largest PTG) was measured by ultrasonography. Patients were divided into 2 groups: group A (MLD ≤9.0 mm [17 HD]); and group B (MLD >9.0 mm [13 HD]). They were defined responder if both the last 2 monthly determinations of inhibit parathyroid hormone (iPTH) were within the target ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text